Biopharma

Multimodal Computational Framework Can Predict Prognosi...

WEDNESDAY, Feb. 26, 2025 -- A multimodal computational framework for patient st...

Schwarzenegger spins ‘Terminator’ catchphrase for Zimme...

Arnie told us he’d be back. Three months after becoming Zimmer Biomet’s chief mo...

Quest Diagnostics to claim Fresenius Medical Care’s kid...

The assets from Fresenius’ Spectra Laboratories subsidiary include water purific...

STAT+: Medicare Advantage enrollment growth slows drast...

Enrollment in private Medicare Advantage plans grew just 3.1%, below projections...

Wearable defibrillator maker Kestra Medical plots $150M...

Kestra's vest-like Assure cardioverter defibrillators have been worn by more tha...

Merck expects oncology king Keytruda to face IRA 'price...

The government price negotiations affecting Keytruda wouldn't take effect until ...

Texas measles outbreak marks first fatality as more cas...

A child in Texas has died from measles, the AP reported, the first death from me...

AstraZeneca’s next breast cancer drug; Madrigal’s accel...

The British drugmaker claimed study success in a first-line setting in breast ca...

Jazz 'active and looking' at M&A deals of 'various size...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-qu...

FDA dings Piramal API plant with Form 483 detailing pro...

Following an inspection of Piramal’s production facility in Maharashtra, India, ...

STAT+: A bill is reintroduced in Congress to revise pro...

The bill would allow Medicare to begin negotiating with pharmaceutical companies...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, ...

Alopexx seeks $11M IPO to advance ex-Sanofi infectious ...

Alopexx is forging ahead with long-gestating plans to go public, updating IPO pa...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab,...

Annex - National provisions for SMEs applicable to the ...

Annex - National provisions for SMEs applicable to the pharmaceutical sector

Certificates Processing System: Demo & Q&A session for ...

Certificates Processing System: Demo & Q&A session for industry stakeholders, On...

Fierce Biotech Fundraising Tracker '25: Eikon's eye-cat...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

STAT+: Are we adopting AI scribes based on… vibes?

The web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guid...

With $27B plan to build 4 new plants, Eli Lilly doubles...

At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indiana...

Eikon remains in megaround mode with $350M series D to ...

Eikon Therapeutics is no stranger to eye-catching funding rounds, and the cancer...

Eli Lilly unveils $27bn US investment as corporate Amer...

Pharmaceutical industry is hoping to ward off growing tariff threat

STAT+: Eli Lilly announces $27 billion investment in U....

Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in th...

Lilly expands US manufacturing build-out with $50B target

The company is doubling plans for capital spending on U.S. factories as Presiden...

With plan to build 4 new plants, Eli Lilly doubles down...

At a press conference in Washington, D.C. dubbed “Lilly in America,” the Indiana...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.